What the FDA labels say about taking them together
Rosuvastatin and sofosbuvir/velpatasvir
Rosuvastatin's FDA label of September 4, 2026 names sofosbuvir/velpatasvir in its drug interactions section, and sofosbuvir/velpatasvir's label names rosuvastatin too. The sofosbuvir/velpatasvir label: “Coadministration of EPCLUSA with rosuvastatin may significantly increase the concentration of rosuvastatin, which is associated with increased risk of myopathy, including rhabdomyolysis. …”
Check it at the source: the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.); the sofosbuvir/velpatasvir FDA label on DailyMed (effective June 5, 2024, Gilead Sciences, Inc.).
What does the rosuvastatin label say about sofosbuvir/velpatasvir?
Rosuvastatin label, drug interactionsAdditional Anti-Viral Medications Prevention or Management: Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/grazoprevir Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Atazanavir/ritonavir Lopinavir/ritonavir Initiate with rosuvastatin 5 mg once daily, and do not exceed a dosage of rosuvastatin 10 mg once daily.
Crestor label (AstraZeneca Pharmaceuticals LP, April 29, 2026), drug interactionsSofosbuvir/velpatasvir
Source: FDA drug label (Crestor, NDA021366), AstraZeneca Pharmaceuticals LP, effective April 29, 2026 (SPL set 325a5d0e-9a72-4015-9fcd-1655fb504cee), via openFDA
Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed
What does the sofosbuvir/velpatasvir label say about rosuvastatin?
Sofosbuvir/velpatasvir label, drug interactionsConcomitant Drug Class/Drug Name: HMG-CoA Reductase Inhibitors: rosuvastatin; Effect on Concentration ↓ = decrease, ↑ = increase.: ↑ rosuvastatin; Clinical Effect/Recommendation: Coadministration of EPCLUSA with rosuvastatin may significantly increase the concentration of rosuvastatin, which is associated with increased risk of myopathy, including rhabdomyolysis. Rosuvastatin may be administered with EPCLUSA at a dose that does not exceed 10 mg.
Source: FDA drug label (Epclusa), Gilead Sciences, Inc., effective June 5, 2024 (SPL set 7f30631a-ee3b-4cfe-866b-964df3f0a44f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rosuvastatin | Sofosbuvir/velpatasvir | |
|---|---|---|
| Labeled for | Heart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention | Hepatitis C |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0692 per tablet 40 mg tablet | $278.03 per unit 400-100 |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once